ACSL4 Inhibition by AS-252424 Protects Visual Function by Suppressing RGC Ferroptosis After Retinal Ischemia...

This study aimed to explore the effects of AS-252424, a selective acyl-CoA synthetase long-chain family member 4 (ACSL4) inhibitor, against retinal ischemia-reperfusion (IR) injury and to elucidate the underlying mechanisms. A mouse model of retinal IR was established, and AS-252424 was administered intravitreally to assess its neuroprotective effect. Retinal ganglion cell (RGC) survival was evaluated by immunofluorescence. Retinal morphology and function were assessed by hematoxylin and eosin staining and electroretinography. Inner retinal neurons were analyzed for morphology and density by immunofluorescence. Expression, localization, and enzymatic activity of ACSL4 were measured by Western blot, immunofluorescence, and ELISA. Ferroptotic lipid peroxidation and oxidative stress were evaluated using malondialdehyde assay, 4-hydroxynonenal immunolabeling, C11-BODIPY 581/591, dihydroethidium probes, and glutathione quantification. Our results confirmed the localization of ACSL4 in human glaucomatous RGCs, with a similar localization pattern observed in mouse retinas. Furthermore, we demonstrated that ACSL4 expression reached its peak on day 1 after IR in mouse retinas. AS-252424 treatment significantly reduced RGC loss after IR. Importantly, AS-252424 achieved comparable RGC protection to Fer-1 at a lower concentration. We also found that AS-252424 preserved inner retinal structural integrity and alleviated edema after IR, as evidenced by quantitative analysis of individual retinal layer thickness. Functionally, AS-252424 significantly restored the amplitudes of the a-wave, b-wave, oscillatory potentials, and photopic negative response. Mechanistically, AS-252424 lowered arachidonic acid-CoA levels and inhibited lipid peroxidation in retinal RGCs after IR, thereby mitigating ferroptotic cell death. AS-252424 can significantly protect retinal structure and function after IR. The underlying mechanism involves the inhibition of ACSL4-mediated ferroptosis. Targeting ACSL4 represents a promising neuroprotective strategy to preserve visual function in ischemic retinopathy.